Why Mohs Surgeons Get Sued: Scar and Cosmetic Claims, Positive Margins, and the Consent Conversation

By John Mahoney · June 2026 · 8 min read

Mohs micrographic surgery is one of the most precise procedures in medicine — a skin cancer is removed in stages, each margin examined under the microscope before the next layer is taken, until the tumor is cleared. It carries one of the highest cure rates of any cancer treatment and a low overall malpractice frequency. But the field's claims are distinctive: they cluster less around oncologic failure and more around appearance, function, and consent. The procedure usually happens on the face, the defect is often larger than the patient pictured, and the result is permanent and visible. For a med-mal attorney, the Mohs file is a cosmetic-and-consent case wrapped around an oncology procedure, and the documents that decide it are the consent form and the stage-by-stage pathology.

This guide walks through why Mohs surgeons get sued — the dominant allegation types, the events that drive the claims, why the consent and pathology record decides defensibility, and how to separate an expected surgical result from a negligent injury — for plaintiff and defense attorneys triaging a dermatologic-surgery case.

Disclaimer: This article is for informational purposes only and does not constitute legal advice. The standard of care in Mohs and dermatologic surgery is jurisdiction- and fact-specific, and consent norms vary. Always verify the controlling standard and the underlying operative, pathology, and consent record before relying on any generalization.

The Frequency and Severity Reality

Dermatologic surgery, including Mohs, is a comparatively low-frequency malpractice area. The procedure is elective and planned, the cure rate is high, and the immediate complication rate is low. Most Mohs claims are not catastrophic in the way an airway or stroke case is — the patient survives, and the cancer is usually cured.

Severity, by contrast, is driven by a different axis: the visible, permanent nature of facial outcomes and the emotional weight patients attach to them. A disfiguring scar, an asymmetric or distorted feature, or a nerve injury affecting facial movement carries real damages and strong jury sympathy even when the cancer was cured. A small subset of claims is genuinely severe — a missed or under-treated aggressive tumor that recurs and metastasizes — but the larger volume is cosmetic and functional dissatisfaction framed as negligence or as a consent failure. As always, treat any cited figure as a starting point and confirm it against the actual record.

The Dominant Allegation Types

Mohs and dermatologic-surgery allegations cluster into a recognizable set spanning technique, oncologic completeness, and consent:

• Disfiguring or unexpected scarring and poor cosmetic outcome — the most common dissatisfaction claim, often framed as negligent technique or inadequate reconstruction.
• Nerve injury — facial-nerve or sensory-nerve damage from a deep or poorly placed excision or repair, with functional and cosmetic consequences.
• Wrong-site or wrong-lesion surgery — operating on the wrong biopsy site, a notorious failure mode in dermatology because biopsy sites heal and become hard to identify; site-verification failures drive these claims.
• Positive margins / failure to clear the tumor — residual cancer left behind, or a recurrence not recognized on surveillance.
• Overtreatment / unnecessary surgery — performing extensive Mohs on a low-risk lesion where a less aggressive approach or observation was reasonable.
• Inadequate informed consent — the patient was not adequately informed of the likely defect size, scar, reconstruction options, functional risk, or the alternative of not treating.

The allegation prior in Mohs surgery is split between technical/cosmetic outcome and consent. The central question is whether the realized scar, defect, or injury reflects a deviation in technique or site verification, or an expected and disclosed consequence of medically appropriate cancer surgery.

The Events That Drive the Claims

Mohs claims concentrate around a short list of recognizable events:

• Wrong-site surgery. The single most preventable Mohs claim. Biopsy sites are notoriously hard to relocate weeks later; failure to confirm the site with photographs, patient verification, or biopsy-site reconciliation drives these cases, and they are difficult to defend when site verification is undocumented.
• A facial defect or scar larger or more distorting than the patient expected — especially where the consent discussion did not set realistic expectations.
• Motor or sensory nerve injury from a deep excision or flap in a high-risk anatomic zone.
• A recurrence after a "cleared" tumor — raising a positive-margin or interpretation question on the stage pathology.
• An aggressive or high-risk tumor under-treated or mismanaged — the rare but high-value oncologic-failure case.
• Postoperative complications — infection, flap or graft necrosis, or bleeding that the plaintiff attributes to negligent technique or aftercare.

Wrong-site surgery and an under-treated aggressive tumor are the cleverage flags in this specialty — the former because it is hard to defend, the latter because it carries the severe damages. A cosmetically imperfect but well-documented, well-consented result on a correctly identified site is the defensible floor. A screen should weight them very differently.

Why the Consent and Pathology Record Decides the Case

Two record sets carry most Mohs cases, and they decide defensibility on opposite axes.

The informed-consent record governs the cosmetic and overtreatment claims. Because so many Mohs disputes are about a result the patient did not expect — a larger defect, a more visible scar, a reconstruction they did not anticipate — a consent form and note that specifically disclosed the likely defect size, the scar, the reconstruction options, the functional risks, and the alternative of observation is the strongest defense in the file. A generic, unsigned, or boilerplate consent that is silent on the realized outcome is the plaintiff's opening.

The operative, mapping, and pathology record governs the oncologic and technical claims. Mohs is documented stage by stage: the lesion location and site verification, the Mohs maps showing each layer taken, the frozen-section interpretations showing clearance, and the reconstruction note. A complete chain — site confirmed, every margin shown clear before stopping, defect closed appropriately — refutes both the wrong-site and the positive-margin theories. Gaps — no documented site verification, an ambiguous map, a stage pathology that does not actually show clearance — become the case. Reading the consent and the stage-by-stage pathology together is what separates a payable error from an expected, disclosed surgical result.

Strong Case vs. Weak Case in Mohs Surgery

Both sides screen the same records for the same signals, and the factors separating a strong case from a weak one are largely symmetrical.

What strengthens a plaintiff's case

• Documented wrong-site or wrong-lesion surgery, or an absence of any site-verification step in the record.
• A consent form silent on the likely defect size, scar, reconstruction, or the option not to treat, paired with a result the patient credibly did not anticipate.
• A Mohs map or stage pathology that does not actually show clearance, followed by a documented recurrence.
• A nerve injury or technical complication inconsistent with a properly performed excision or repair in that anatomic zone.

What strengthens the defense

• A specific, signed, contemporaneous consent disclosing the defect, scar, reconstruction options, functional risks, and alternatives.
• Documented site verification — photographs, patient confirmation, biopsy-site reconciliation — before incision.
• Complete Mohs maps and stage pathology showing the tumor cleared before stopping, with appropriate reconstruction.
• A realized scar or defect that was an expected, disclosed consequence of medically necessary cancer surgery — the recognized-outcome defense.

Many Mohs cases turn on consent and expectation-setting rather than surgical breach. A cured cancer and a technically sound excision can still generate a viable claim if the consent record did not prepare the patient for the result — so screen the consent conversation as carefully as the pathology.

The Expert and Merit Questions Come Early

Because Mohs claims turn on a specialized surgical and oncologic standard of care, the expert is central and the qualification fight starts at the pre-suit gate. Most cases need a fellowship-trained Mohs surgeon or an experienced dermatologic surgeon, with plastic or facial-plastic surgery and dermatopathology experts added where reconstruction, nerve injury, or margin interpretation is at issue. The expert who signs the certificate of merit must typically be qualified to opine against the defendant, and the same specialty-match and reliability questions feed directly into a later motion to exclude. Screening for both at intake prevents the avoidable losses — the strong wrong-site case dismissed on a defective merit filing, or the expert who clears the merit gate but cannot survive a reliability challenge.

Bottom Line

Mohs surgery is a low-frequency specialty whose claims are driven by appearance, function, and consent rather than by oncologic failure. The dominant allegations are disfiguring scarring, nerve injury, wrong-site surgery, positive margins, overtreatment, and inadequate informed consent. Most claims are not catastrophic, but facial outcomes are permanent and visible and carry real damages and jury sympathy. The consent record and the stage-by-stage Mohs pathology are the case: complete and specific, they are a powerful defense; generic or gapped, they are the plaintiff's strongest exhibits.

For both sides, the work is the same: read the consent conversation as carefully as the pathology, confirm site verification and stage-by-stage clearance, separate the rare under-treated aggressive tumor from the cosmetic-dissatisfaction case, and confirm the expert match and merit filing early. The merits should decide the case — so verify every generalization against the actual record.

Questions? Contact us at [email protected] or (856) 979-6525

🔎 Screening a case in a different specialty? Browse all specialty malpractice-risk guides in one place — Why Doctors Get Sued: Malpractice Risk by Specialty →